DCGI has already given emergency use authorization (EUA) to Bharat Biotech for the intranasal vaccine for ages 18 and above.
Earlier, ANI reported quoting the Subject Expert Committee (SEC) members of DCGI as saying that the five arms heterologous intranasal booster dose - iNCOVACC (BBV154) - means, “Arm 1: 2 covaxin – booster covaxin, Arm 2: 2 covaxin – booster I/N vaccine, Arm 3: 2 Covishield- booster Covishield, Arm 4: 2 Covishield- booster I/N vaccine, Arm 5: 2 intranasal- booster intranasal.
The pharma company in its earlier statement said iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.
The company had stated iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy.
According to it, iNCOVACC has the double benefit of enabling faster development of variant specific vaccines and easy nasal delivery that enables mass immunization to protect from emerging variants of concern. It promises to play a significant role in mass immunisation campaigns during pandemics and endemics.The vaccine maker had also stated that iNCOVACC is stable at 2-8°C for easy storage and distribution. It had stated the compnay has established large manufacturing capabilities at multiple sites across India, including Gujarat, Karnataka, Maharashtra and Telangana with operations pan India.